Given the distinct immunological landscape associated with MSI tumors—including upregulated expression of immune checkpoints such as PD-1, PD-L1, and CTLA-4—it could be hypothesized that TIM-3 expression would similarly be increased in MSI CRC. The gene discussed is CD274; the disease is colorectal carcinoma.